Skip to content


  • Poster presentation
  • Open Access

Flow cytometry immunophenotyping of peripheral blood circulating B-cell subset: comparison of osteoarthritis, chronic lymphocytic leukemia patients and normal donors

  • 1,
  • 1 and
  • 1, 2
Journal of Translational Medicine20119 (Suppl 2) :P20

  • Published:


  • Chronic Lymphocytic Leukemia
  • Lymphoproliferative Disorder
  • Normal Donor
  • Chronic Lymphocytic Leukemia Patient
  • Cartilage Degeneration


Peripheral blood (PB) circulating B-cell subsets have been poorly defined until ≥6-color flow cytometry (FC) became available [1]. Traffic of the B-cell subsets between tissues through PB reflects the immune status of an individual subject and potentially also disorders of B-cell development, autoimmunity, and lymphoproliferative diseases [2].

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western world. It is a chronic lymphoproliferative disorder characterized by the accumulation of monoclonal B cells in the blood, bone marrow, and secondary lymphoid tissues [3]. Osteoarthritis (OA) is the most common articular disease worldwide. Immune system cells are involved in the matrix degradation that characterizes cartilage degeneration in OA [4].


The aim of our study was to quantify and compare proportions of B-cell sub-populations in PB of CLL, OA patients and normal donors (ND).

Patients and methods

PB samples were collected from 10 patients diagnosed with CLL, 4 patients diagnosed with OA and 9 ND. Conjugated monoclonal antibodies against CD19, CD10, CD27, CD38 and CD5 were used for immunophenotyping. Fluorescence measurements were made by BD FACS Aria II. BD FACS Diva 6.2 software was used to analyze data. Descriptive statistics were used to analyze data and summarize baseline characteristics.


Four subpopulations of B-cells were detected in peripheral blood samples: CD19+CD10+CD27-CD38+CD5++ immature B-cells - 20,7% (CLL), 41,2% (OA); 11,4% (ND); CD19+CD10-CD27+CD38+/-CD5- plasmatic B-cells – 5,4% (CLL), 9,4% (OA), 3,1% (ND); CD19+CD10-CD27++CD38++CD5- memory B-cells – 29,8 (CLL), 23,5% (OA), 28,4% (ND); CD19+CD10-CD27-CD38+/-CD5+/- naïve B-cells – 40,3% (CLL), 25.7% (OA), 56,8% (ND). Marked increase in immature and plasmatic B-cell number was found in OA and CLL patients.


The frequency of immature and plasmatic B-lymphocytes in PB has been found to be increased in OA and CLL. Changes in B-cell subpopulation profile may be proposed as a disease development indicator.

Authors’ Affiliations

A. Kirchenstein Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia
Hematology Dept., Riga Eastern University Hospital, Riga, Latvia


  1. Caraux A, Klein B, Paiva B: Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica. 2010, 95 (6): 1016-1020. 10.3324/haematol.2009.018689.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Perez-Andres M: Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010, 78 (Suppl 1): S47-60.View ArticlePubMedGoogle Scholar
  3. Faguet GB: Chronic lymphocytic leukemia: an updated review. J Clin Oncol. 1994, 12: 1974-1990.PubMedGoogle Scholar
  4. Poole AR: An introduction to the pathophysiology of osteoarthritis. Front Biosci. 1999, 4: D662-70. 10.2741/Poole.View ArticlePubMedGoogle Scholar


© Spaks et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.